What question did this study set out to answer?

To report a rare case of isolated CNS relapse of FLT3-ITD positive AML and its treatment.

January 18, 2026Clinical Case ReportsOpen Access

Gilteritinib in an Isolated CNS Recurrence of FLT3 ‐ ITD Positive AML

View Full Paper

Ask AI

Bookmark

Authors

Case report shows targeted therapy improves outcomes in isolated CNS relapse of AML, suggesting new treatment approaches.

To report a rare case of isolated CNS relapse of FLT3-ITD positive AML and its treatment.
Described a case of an 82-year-old patient with isolated CNS relapse of AML.
Analyzed cerebrospinal fluid (CSF) for blast cells with FLT3-ITD.
Administered gilteritinib, a FLT3 tyrosine kinase inhibitor, while the patient was on palliative chemotherapy.
Achieved complete remission after gilteritinib treatment.
Cleared FLT3-ITD from the cerebrospinal fluid (CSF).

Silva‐Bermudez et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark